Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Interrupción para sentarse y salud cardiovascular de todo el cuerpo (SWITCH)

22 de septiembre de 2026 actualizado por: University of North Carolina, Chapel Hill

La Interrupción de Sentarse y la Salud Cardiovascular de Todo el Cuerpo: Vinculación de las Respuestas Fisiológicas a los Comportamientos de Riesgo

There is strong evidence for the association between sedentary behaviors and cardiovascular diseases such as coronary heart disease and stroke. However, the public currently has no clear guidance on how to limit or interrupt their sedentary behaviors. This study will identify and test the physiological effects of several sedentary behavior interruption strategies and explore the feasibility (i.e., likelihood of an individual performing the requested activities) of those strategies to inform the development of public policy surrounding sedentary behavior interruption. Long-term, the findings of this study will inform a large clinical trial that can test whether sedentary behavior reduction can decrease cardiovascular disease risk.

Descripción general del estudio

Descripción detallada

Sedentary behaviors (SB) are biologically distinct but understudied heart disease risk factors. National and international agencies have concluded that the level of evidence for an overall and dose-response association between SB and heart disease mortality is moderate-strong. These agencies do not provide specific recommendations for breaking-up SB, though do call on the research community to facilitate policy development by establishing biological plausibility, identifying the optimal dose for SB substitution strategies, and conducting randomized clinical trials to test the efficacy of these strategies. Accordingly, the goal of this study is to identify mechanism-informed, socioecological-based SB substitution recommendations to reduce heart disease risk. To achieve this goal, two aims will be addressed. Aim 1 will identify a feasible SB substitution strategy to prevent the negative cardiovascular responses to prolonged SB (i.e., strategies that people will actually follow). Adverse cardiovascular responses to prolonged SB will be measured using aortic arterial stiffness (AS), a noninvasive test that predicts future heart disease. To accomplish this aim, middle-aged (30-60 years) participants will provide written informed consent, prior to the measurement of aortic AS and associated mechanistic responses to the following over 4 hours, in a randomized crossover manner: (i) SB with a 5-minute walk break once per hour; (ii) SB with a 15-minute standing break once per hour; (iii) SB with two breaks per hour, alternating between a 5-minute walk and a 15-minute stand; and (iv) SB with no breaks (control). These strategies were selected based on extensive prior work by the investigators, and because they are feasible, which is a key component of this study. SB reduction strategies will only decrease heart disease risk if people are willing to adhere to future SB substitution recommendations. To increase the likelihood of feasibility and long-term adherence, Aim 2 will evaluate the determinants of SB using a socioecological model. This recognizes that behavior change is likely to be limited if the physical and sociocultural environments do not support the behavior change. To accomplish Aim 2, a combined inductive-deductive qualitative approach will be used. Participants who complete Aim 1 will participate in focus groups (min 3, max 8 participants/group). Crucially, the outcomes from this proposal will be instrumental in helping to design a subsequent clinical trial to test a mechanism-informed yet feasible SB reduction intervention, and in doing so directly support the development of SB policy.

Tipo de estudio

Intervencionista

Inscripción (Actual)

58

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • University of North Carolina at Chapel Hill

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

30 años a 60 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Aged between 30-60 years
  • Insufficiently active: self-reported exercise <90 minutes per week for the past 3 months
  • Sedentary: self-reported sitting >8 hours per day
  • Self-reported ability to walk 4 blocks and climb 2 flights of stairs
  • Possession of cellular phone able to receive text messages

Exclusion Criteria:

  • Use of assisted-walking devices
  • Comorbid condition that would limit the ability to reduce sedentary behavior (e.g., musculoskeletal condition, current chemotherapy)
  • Plans for major surgery within next 3 months
  • Recent history (<1 year) of ischemic heart disease, chronic heart failure, stroke, or chronic kidney disease
  • Recent (< 1 year) or planned bariatric surgery
  • Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg
  • Current or recent (within last 6 months) pregnancy; current or recent (within last 3 months) breastfeeding
  • Morbidly obesity (BMI >40 kg/m^2) or underweight (BMI <18.5 kg/m^2)
  • Use of anti-hypertensive drugs
  • Use of glucose-controlling medication
  • Heavy alcohol consumption (>15 drinks per week)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: One 5-Minute Walking Bout Each Hour

A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.

The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed.

One 5-minute light intensity walking break per hour throughout the 4-hour SB condition

Comparador activo: One 15-Minute Standing Bout Each Hour

A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.

The interruption strategy includes breaking up the 4-hour sitting bout with one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed.

One 15-minute standing break per hour throughout the 4-hour SB condition

Comparador activo: One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour

A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.

The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout and one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed.

Two breaks per hour throughout the 4-hour SB condition, alternating between a 5-minute light intensity walking break and a 15-minute standing break

Comparador activo: Uninterrupted Sitting

A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.

This uninterrupted sedentary bout will serve as a control. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed.

No breaks will be provided throughout the 4-hour SB condition. This will be used as the control condition

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean Change in Carotid-femoral Pulse Wave Velocity (cfPWV)
Periodo de tiempo: Measurements will be taken immediately before and after each 4-hour SB condition

cfPWV (m/sec) will be measured between the carotid and femoral arteries, using a collar around the neck and a cuff around the thigh, with the participant in a supine position. cfPWV is calculated by dividing path length by pulse transit time and reported as the mean of three measurements

Measurements will be taken immediately before and after each 4-hour SB condition

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Heart-middle Cerebral Artery Pulse Wave Velocity (Brain PWV)
Periodo de tiempo: Measurements will occur continuously throughout each of the 4-hour SB conditions

Brain PWV (cm/sec) is the velocity at which a pressure wave travels between the heart and cerebrovascular system. Brain PWV will be calculated from the ECG r-wave to the foot of the Cerebral Blood Flow Velocity (CBFV) waveform

Measurements will occur continuously throughout each of the 4-hour SB conditions
Mean Change in Femoral-ankle PWV
Periodo de tiempo: Measurements will be taken immediately before and after each 4-hour SB condition

Femoral-ankle PWV (m/sec) is the velocity at which a pressure wave travels between the femoral-ankle arterial segments. Femoral-ankle PWV is calculated by dividing path length by pulse transit time and reported as the mean of three measurements

Measurements will be taken immediately before and after each 4-hour SB condition

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Erik Hanson, PhD, University of North Carolina, Chapel Hill

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de agosto de 2022

Finalización primaria (Actual)

30 de mayo de 2026

Finalización del estudio (Actual)

30 de mayo de 2026

Fechas de registro del estudio

Enviado por primera vez

30 de marzo de 2022

Primero enviado que cumplió con los criterios de control de calidad

30 de marzo de 2022

Publicado por primera vez (Actual)

7 de abril de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 21-3195
  • 1R01HL157187-01A1 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina.

Marco de tiempo para compartir IPD

Beginning 9 months following publication and continuing for 36 months

Criterios de acceso compartido de IPD

Investigator has IRB, IEC, or REB approval and an executed data use/sharing agreement with UNC.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir